Low-grade gliomas tend to vary quite a bit, from a biological standpoint and how they respond to treatment.
In order to better understand and optimize the use of temozolomide in a clinical setting, UCSF researcher Dr. Joseph Costello is studying how this drug affects the genetic makeup of lower grade gliomas over time.
Dr. Costello and his team have discovered that recurrent gliomas may have genetic profiles that are markedly different from those of the initial tumors that spawned them, and have shown that these differences are vastly amplified when a commonly used chemotherapy drug, temozolomide (TMZ), is employed to treat the initial tumors.
The results of their study, published online in Science Express on December 12, 2013, may prompt a rethinking of targeted approaches to glioma treatment based on genetic profiling of tumors, and also argues for the judicious use of TMZ, the chemotherapy agent most often used in glioma cases.
Accelerate Brain Cancer Cure is a Washington DC-based venture philanthropy 501(c)(3) nonprofit organization that drives cutting-edge research and treatments for brain tumors. Copyright 2014 ABC2 - All Rights Reserved.